Company Encyclopedia
View More
name
GZBL
002424.SZ
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines and honey. Its products are used for cardiovascular, cough, cold, gynecological, and pediatric areas. The company was incorporated in 1999 and is headquartered in Anshun, China.
3.159 T
002424.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking125/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.07%D
    • Profit Margin0.07%D
    • Gross Margin58.34%B
  • Growth ScoreD
    • Revenue YoY-25.47%E
    • Net Profit YoY100.48%A
    • Total Assets YoY-12.13%E
    • Net Assets YoY-6.07%D
  • Cash ScoreC
    • Cash Flow Margin141940.39%A
    • OCF YoY-25.47%E
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreC
    • Gearing Ratio47.78%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    GZBL: Net profit for the third quarter was 4.9798 million yuan, a year-on-year increase of 559.90%

    GZBL announced that the revenue for the third quarter was 640 million yuan, a year-on-year increase of 1.11%; the net profit was 4.9798 million yuan, a year-on-year increase of 559.90%. The revenue for the first three quarters was 2.102 billion yuan, a year-on-year decrease of 24.28%; the net profit was 56.8144 million yuan, a year-on-year decrease of 35.60%

    Zhitong·
    SZ
    002424
    +5.94%
    Zhitong·
    SZ
    002424
    +5.94%

    The concept of innovative drugs continues to rebound, with GZBL and Luoxin Pharmaceutical both hitting the daily limit

    The concept of innovative drugs continues the rebound momentum from yesterday, with GZBL and Luoxin Pharmaceutical hitting the daily limit, Sanofi's stock rising over 10%, and Laimei Pharmaceutical, Hainan Haiyao, Guangshengtang, and Yifang Biotechnology also following suit

    Zhitong·
    SZ
    002793
    -0.56%
    SZ
    002424
    +5.94%
    Zhitong·
    SZ
    002793
    -0.56%
    SZ
    002424
    +5.94%

    The traditional Chinese medicine sector fluctuated and surged, with GZBL hitting the limit up

    The traditional Chinese medicine sector experienced a volatile rise, with GZBL hitting the limit up, and Weikang Pharmaceutical, Darentang, Fangsheng Pharmaceutical, Panlong Pharmaceutical, and Wohua Pharmaceutical following suit. In terms of related ETFs, the traditional Chinese medicine ETF had a transaction volume of 15.1552 million yuan. On October 15th, GZBL announced that its subsidiary "Bailing Yuxiu Pharmaceutical Co., Ltd." has once again received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration's Drug Evaluation Center, allowing the clinical trial of the traditional Chinese medicine Class 1 new drug Tangning Tongluo Tablets for the treatment of Type 2 diabetes

    Zhitong·
    SZ
    002424
    +5.94%
    Zhitong·
    SZ
    002424
    +5.94%

    GZBL: The clinical trial application for Tangning Tongluo tablets has been approved

    According to the Zhitong Finance APP, GZBL announced that its wholly-owned subsidiary Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. (referred to as "Bailing Yuxiu") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The clinical trial application for Tangning Tongluo tablets submitted by Bailing Yuxiu has been approved, allowing the product to conduct clinical trials for Type 2 diabetes

    Zhitong·
    SZ
    002424
    +5.94%
    Zhitong·
    SZ
    002424
    +5.94%

    GZBL: The capacity expansion and technological transformation project has been completed and put into production, increasing the processing capacity of traditional Chinese medicinal materials to 60,000 tons per year

    GZBL announced in its 2025 semi-annual report that its capacity expansion and technological transformation project has been completed and put into production, increasing the pre-processing capacity of traditional Chinese medicinal materials from 25,000 tons/year to 60,000 tons/year, enhancing the industry's scale advantage. The company has established business relationships with over 80% of end customers nationwide, with more than 600,000 end customers and over 100,000 signed VIP customers

    Zhitong·
    SZ
    002424
    +5.94%
    Zhitong·
    SZ
    002424
    +5.94%
    © 2025 Longbridge｜Disclaimer